Medtronic (MDT) Stock Forecast & Price Target

Compare

6,138 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDT Analyst Ratings

Moderate Buy

13 Buy

11 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Medtronic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDT Stock 12 Month Forecast

Average Price Target

$96.32

▲(8.74%Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is $96.32 with a high forecast of $110.00 and a low forecast of $87.00. The average price target represents a 8.74% change from the last price of $88.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"73":"$73","92":"$92","111":"$111","82.5":"$82.5","101.5":"$101.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96.32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$96.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$87.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[73,82.5,92,101.5,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.75,90.38461538461539,92.01923076923077,93.65384615384616,95.28846153846153,96.92307692307692,98.5576923076923,100.1923076923077,101.82692307692308,103.46153846153847,105.09615384615384,106.73076923076923,108.36538461538461,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.75,89.3323076923077,89.91461538461539,90.49692307692308,91.07923076923076,91.66153846153846,92.24384615384615,92.82615384615384,93.40846153846154,93.99076923076923,94.57307692307691,95.1553846153846,95.7376923076923,{"y":96.32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.75,88.61538461538461,88.48076923076923,88.34615384615384,88.21153846153847,88.07692307692308,87.9423076923077,87.8076923076923,87.67307692307692,87.53846153846153,87.40384615384616,87.26923076923077,87.13461538461539,{"y":87,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":74.64,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.9,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$96.32

Lowest Price Target$87.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$98

Buy

10.63%

Upside

Reiterated

06/25/25

Medtronic scores well due to its solid financial performance and strategic focus on high-growth areas. The company's earnings call provided a positive outlook with revenue growth and strategic initiatives like the Diabetes business spin-off. However, valuation concerns and potential impacts from tariffs and currency headwinds temper the overall score.

Mike KratkyLeerink Partners

Leerink Partners

$110

Buy

24.18%

Upside

Reiterated

07/09/25

Medtronic (MDT) Receives a Buy from Leerink Partners

Vijay KumarEvercore ISI

Evercore ISI

$103→$106

Buy

19.67%

Upside

Reiterated

07/08/25

Evercore ISI Sticks to Their Buy Rating for Medtronic (MDT)

Joanne WuenschCiti

Citi

$98→$99

Buy

11.76%

Upside

Reiterated

07/07/25

Medtronic price target raised to $99 from $98 at CitiMedtronic price target raised to $99 from $98 at Citi

Larry BiegelsenWells Fargo

Wells Fargo

$98

Buy

10.63%

Upside

Reiterated

06/30/25

We rate MDT Overweight, as we believe that the company will benefit as underlying medtech markets improve as staffing shortages ease in major markets.

Michael PolarkWolfe Research

Wolfe Research

―

Hold

―

Upgraded

06/30/25

Medtronic upgraded to Peer Perform from Underperform at Wolfe ResearchMedtronic upgraded to Peer Perform from Underperform at Wolfe Research

Ryan ZimmermanBTIG

BTIG

―

Hold

―

Reiterated

06/26/25

Medtronic (MDT) Receives a Hold from BTIGWe note though that in January 2025 MDT received CE Mark for its BrainSense Adaptive DBS System and then in February 2025 MDT picked up FDA clearance but Percept DBS has been growing in the high-single-digit to mid- teens range over the past 4 quarters.

Josh JenningsTD Cowen

TD Cowen

$95

Buy

7.25%

Upside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Shagun Singh ChadhaRBC Capital

RBC Capital

―

Buy

―

Reiterated

06/18/25

Medtronic (MDT) Receives a Buy from RBC Capital

Travis SteedBank of America Securities

Bank of America Securities

$100

Buy

12.89%

Upside

Reiterated

06/09/25

Medtronic (MDT) Gets a Buy from Bank of America Securities

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

06/06/25

Medtronic's Diabetes Division Spin-Off: Hold Rating Amid Modest Immediate Value Potential

Matt MiksicBarclays

Barclays

$109

Buy

23.05%

Upside

Reiterated

06/05/25

Medtronic (MDT) Receives a Buy from Barclays

Nico ChenDBS

DBS

$90

Hold

1.60%

Upside

Reiterated

05/30/25

Medtronic's Hold Rating: Navigating Profit Decline, Innovation Challenges, and Market Threats

David ToungArgus Research

Argus Research

$120→$105

Buy

18.54%

Upside

Reiterated

05/27/25

Medtronic price target lowered to $105 from $120 at ArgusMedtronic price target lowered to $105 from $120 at Argus

Rick WiseStifel Nicolaus

Stifel Nicolaus

$85→$87

Hold

-1.78%

Downside

Reiterated

05/27/25

Stifel Nicolaus Reaffirms Their Hold Rating on Medtronic (MDT)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$98

Buy

10.63%

Upside

Reiterated

06/25/25

Mike KratkyLeerink Partners

Leerink Partners

$110

Buy

24.18%

Upside

Reiterated

07/09/25

Medtronic (MDT) Receives a Buy from Leerink Partners

Vijay KumarEvercore ISI

Evercore ISI

$103→$106

Buy

19.67%

Upside

Reiterated

07/08/25

Evercore ISI Sticks to Their Buy Rating for Medtronic (MDT)

Joanne WuenschCiti

Citi

$98→$99

Buy

11.76%

Upside

Reiterated

07/07/25

Medtronic price target raised to $99 from $98 at CitiMedtronic price target raised to $99 from $98 at Citi

Larry BiegelsenWells Fargo

Wells Fargo

$98

Buy

10.63%

Upside

Reiterated

06/30/25

We rate MDT Overweight, as we believe that the company will benefit as underlying medtech markets improve as staffing shortages ease in major markets.

Michael PolarkWolfe Research

Wolfe Research

―

Hold

―

Upgraded

06/30/25

Medtronic upgraded to Peer Perform from Underperform at Wolfe ResearchMedtronic upgraded to Peer Perform from Underperform at Wolfe Research

Ryan ZimmermanBTIG

BTIG

―

Hold

―

Reiterated

06/26/25

Josh JenningsTD Cowen

TD Cowen

$95

Buy

7.25%

Upside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Shagun Singh ChadhaRBC Capital

RBC Capital

―

Buy

―

Reiterated

06/18/25

Medtronic (MDT) Receives a Buy from RBC Capital

Travis SteedBank of America Securities

Bank of America Securities

$100

Buy

12.89%

Upside

Reiterated

06/09/25

Medtronic (MDT) Gets a Buy from Bank of America Securities

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

06/06/25

Medtronic's Diabetes Division Spin-Off: Hold Rating Amid Modest Immediate Value Potential

Matt MiksicBarclays

Barclays

$109

Buy

23.05%

Upside

Reiterated

06/05/25

Medtronic (MDT) Receives a Buy from Barclays

Nico ChenDBS

DBS

$90

Hold

1.60%

Upside

Reiterated

05/30/25

Medtronic's Hold Rating: Navigating Profit Decline, Innovation Challenges, and Market Threats

David ToungArgus Research

Argus Research

$120→$105

Buy

18.54%

Upside

Reiterated

05/27/25

Medtronic price target lowered to $105 from $120 at ArgusMedtronic price target lowered to $105 from $120 at Argus

Rick WiseStifel Nicolaus

Stifel Nicolaus

$85→$87

Hold

-1.78%

Downside

Reiterated

05/27/25

Stifel Nicolaus Reaffirms Their Hold Rating on Medtronic (MDT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

1 Month

xxx

Success Rate

17/29 ratings generated profit

Average Return

+1.33%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.62% of your transactions generating a profit, with an average return of +1.33% per trade.

3 Months

xxx

Success Rate

15/20 ratings generated profit

Average Return

+3.83%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +3.83% per trade.

1 Year

Larry BiegelsenWells Fargo

Success Rate

23/29 ratings generated profit

Average Return

+6.77%

reiterated a buy rating 10 days ago

Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 79.31% of your transactions generating a profit, with an average return of +6.77% per trade.

2 Years

xxx

Success Rate

20/23 ratings generated profit

Average Return

+7.25%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.96% of your transactions generating a profit, with an average return of +7.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDT Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDT has received 34 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. MDT average Analyst price target in the past 3 months is 96.32.

Each month's total comprises the sum of three months' worth of ratings.

MDT Financial Forecast

MDT Earnings Forecast

Next quarter’s earnings estimate for MDT is $1.23 with a range of $1.22 to $1.24. The previous quarter’s EPS was $1.62. MDT beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year MDT has Outperformed its overall industry.

MDT Sales Forecast

Next quarter’s sales forecast for MDT is $8.37B with a range of $8.32B to $8.48B. The previous quarter’s sales results were $8.93B. MDT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year MDT has Outperformed its overall industry.

MDT Stock Forecast FAQ

What is MDT’s average 12-month price target, according to analysts?

Based on analyst ratings, Medtronic’s 12-month average price target is 96.32.

What is MDT’s upside potential, based on the analysts’ average price target?

Medtronic has 8.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDT a Buy, Sell or Hold?

Medtronic has a consensus rating of Moderate Buy which is based on 13 buy ratings, 11 hold ratings and 0 sell ratings.

What is Medtronic’s price target?

The average price target for Medtronic is 96.32. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $87.00. The average price target represents 8.74% Increase from the current price of $88.58.

What do analysts say about Medtronic?

Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of MDT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Medtronic (MDT) Stock Forecast & Price Target

MDT Analyst Ratings

MDT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medtronic

MDT Analyst Recommendation Trends

MDT Financial Forecast

MDT Earnings Forecast

MDT Sales Forecast

MDT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts